Clinical Study
Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes
Table 4
Baseline and 12-month BCVA related to the numbers of implants and vitrectomy.
| | Baseline BCVA | 12-month BCVA | value |
| Number of implants | | | | All eyes | 0.13 (0.00–1.00) | 0.33 (0.01–1.00) | <0.001 | 1 | 0.20 (0.00–0.67) | 0.33 (0.01–1.00) | 0.001 | 2 | 0.20 (0.01–1.00) | 0.50 (0.01–1.00) | 0.041 | 3 | 0.10 (0.00–0.33) | 0.33 (0.10–0.80) | <0.001 | 4 | 0.08 (0.01–0.20) | 0.50 (0.20–0.80) | 0.068 |
| Vitrectomized | | | | No | 0.20 (0.00–1.00) | 0.33 (0.01–1.00) | 0.001 | Yes | 0.11 (0.01–0.40) | 0.45 (0.01–0.80) | <0.001 |
|
|
BCVA, best-corrected visual acuity. Wilcoxon test.
|